Clinical Read2026-06-05

Aleniglipron (GSBR-1290) - (ACCESS and ACCESS II )

Structure Therapeutics Inc.GPCR
Indication
Type 2 Diabetes, obesity
Stage
phase2
Event
Phase 2b